Target- |
Mechanism- |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions
A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions
Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion
100 Clinical Results associated with Abnoba Korea, Inc.
0 Patents (Medical) associated with Abnoba Korea, Inc.
100 Deals associated with Abnoba Korea, Inc.
100 Translational Medicine associated with Abnoba Korea, Inc.